Ligands and receptors
You will be able to: Explain why binding, signaling and delivering a payload are different functions.
A ligand is a molecule that binds a receptor or another defined binding partner. Binding may activate a signal, block it or deliver something. It does not always activate a receptor, and a binding interaction does not always produce the intended biological effect.
The useful analogy and its limit
A key and lock suggest selective recognition. Real molecular surfaces are flexible: binding strength varies, several molecules may bind the same site, and one ligand can have more than one partner. The analogy explains recognition better than it explains what happens afterward.
Binding is the beginning of a mechanism, rather than proof of its final effect.
Three examples
| Interaction | What binds | What changes |
|---|---|---|
| PD-L1 (programmed death-ligand 1) and PD-1 | A checkpoint ligand and a receptor on immune cells | Inhibitory signaling can limit T-cell responses |
| Anti-PD-1 antibody and PD-1 | A therapeutic antibody and its target | Blocks an inhibitory interaction; benefit still depends on immune and clinical context |
| Targeting binder and an accessible protein | A drug's recognition component and its target | Can localize a chemical or radiation payload without the target being a growth driver |
FAP, for example, is a cell-surface protease that can be a targeting address. Calling it a receptor that turns on a tumor-killing signal confuses delivery with signaling.
Two cancer-relevant distinctions
HER2 has no known direct ligand. It can participate in signaling pairs with other receptors in its family, including ligand-bound partners. A textbook diagram should not depict a generic growth factor binding directly to HER2. HER2 staining and ADC (antibody-drug conjugate) eligibility are also separate from proving that a tumor depends on HER2 signaling.
A TCR (T-cell receptor) recognizes peptide plus HLA (human leukocyte antigen). For conventional T cells, the relevant binding partner is a peptide–HLA complex, not a free neoantigen peptide or an intact intracellular protein. Many receptors can recognize related complexes, and recognition still needs functional context.
Try it
An antibody binds a tumor protein. Has it been shown to stop tumor growth?
Explain it back: No. Binding may localize the antibody, but signaling blockade, immune recruitment or payload delivery must be demonstrated. Safety and patient benefit require further evidence.
Explain it back
Ask what binds, what changes after binding and which downstream effect was measured.
Takeaway
Ask what binds, what changes after binding and which downstream effect was measured.
Next: HLA, dendritic cells and targeted-therapy mechanisms.
Sources
Checked October 8, 2026.
- HER2–HER3 structural study — ligand binding and receptor partnership are different.
- FDA tebentafusp review — peptide–HLA recognition by a TCR-based drug.
- NCI: monoclonal antibodies.